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INTRODUCTION:  A positive  ﬁnding  of metastatic  melanoma  in  a  sentinel  lymph  node  is an ominous  sign
and  a strong  predictor  of overall  survival.  In contrast,  current  data  trends  have  shown  that  patients  with
benign  nevus  cells  in  the  sentinel  nodes  do  not  require  additional  therapy  since  their  prognosis  has
been  shown  to be  similar  to that  of  patients  with  negative  lymph  nodes.  Distinguishing  between  benign
capsular  nevi  and  metastatic  melanoma  often  proves  to  be diagnostically  problematic.
CASE PRESENTATION:  In  this  case  report  we present  two  cases  of  melanoma  in  which  sentinel  lymph  node
biopsies  proved  to  be  difﬁcult  in distinguishing  metastatic  melanocytes  from  capsular  nevus  cells.  In  both
cases,  further  workup  was  necessary  for accurate  diagnoses.
DISCUSSION:  A  lack of  standardized  distinctions  of  benign  nevus  cell  from  melanoma  pose  a diagnostic
pitfall.  Assigning  a diagnosis  of malignant  melanoma  might  seem  like  the  safer  approach  to  avoid  a  false
negative,  but  the  resultant  treatment,  including  the  possibility  of  additional  surgical  complications,  may
cause anxiety,  discomfort,  and ﬁnancial  instability  for the patient.  Current  methods  of  distinguishing  the
two  based  solely  on  histology  may  be insufﬁcient  due  to  similar  pathologic  patterns.
CONCLUSION:  To  avoid  misdiagnosing  a patient  and performing  unnecessary  therapy,  it would  be  ben-
eﬁcial  to get  a second  opinion  by  additional  histopathologists  at a high  volume  center.  Additionally,
immunohistochemical  staining  should  be  carefully  employed  due  to some  overlap  in  commonly  used
markers.  Using  tissue  morphology  in  conjunction  with  immunohistochemical  staining  may  be the  best
way to  make  the  most  accurate  diagnosis.
© 2016  The  Authors.  Published  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Background
According to the American Joint Commission on Cancer (AJCC)
tandards, melanoma patients with speciﬁc primary lesions should
ndergo a sentinel lymph node biopsy for proper staging and diag-
osis. AJCC guidelines for sentinel lymph node biopsy have been
ecently updated to include patients who have been staged as T1b
rimary lesions (≤1.0 mm Breslow thickness with ulceration or
itoses ≥1 mm2) [1,2]. Thus, the increased use of sentinel lymph
ode biopsies in patients with melanoma have led to a higher fre-
uency of nodal nevi discovered in regional lymph nodes [3,4].
ncidence of nodal aggregates of benign nevus cells in sentinel
ymph node biopsies have shown to be as high as 22% in melanoma
ases and often present in a conﬁned ﬁbrous capsule or trabeculae
f lymph nodes [5,6].
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210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A positive ﬁnding of metastatic melanoma in a sentinel lymph
node is an ominous sign and a strong predictor of overall sur-
vival and progression [4]. In contrast, patients with benign nodal
nevus aggregates have been shown to present with a 5 year sur-
vival similar to that of patients who had no positive ﬁndings
on sentinel lymph node biopsies [7,8]. Thus, the differentiation
between the nodal nevi and metastatic lymph nodes has a pro-
found effect on the prognosis of the patient, as the recognition of
the differences is important to avoid misdiagnosis and provide ade-
quate therapy options [7–9]. Current gold standard for diagnosis of
metastatic melanoma has been tissue morphology and histopathol-
ogy; however, benign melanocytic nevus cells are often difﬁcult to
distinguish from metastatic melanoma [2,3,6,9,10].
In this case report, which is in compliance with the CAse REport
(SCARE) Guidelines, we  present two cases of melanoma in which
sentinel lymph node biopsies proved to be difﬁcult in distinguish-
ing metastatic melanocytes from capsular nevus cells [11]. In both
cases, further workup was  necessary for accurate diagnosis of
disease status. We  believe that advanced histopathological tech-
niques should be employed in these scenarios given the signiﬁcant
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Case 1: H & E section of skin of left forearm after wide excision of melanoma
40x. Central area of organizing inﬂamed re-epithalized scar. The biopsy site at
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Fig. 2. Case 1: H & E view of the sentinel lymph node shows portions of capsule to
be  cauterized with central hilar fatty replacement. Sinus histiocytes are scattered in
moderate numbers in the sinusoids. Indicative of capsular nevus.
Fig. 3. Case 1: S-100 immunostain shows 0.4 mm focus of small bland appearing
cells within the capsule of sentinel lymph node that are not discretely identiﬁablehe  edge where this is focal residual malignant melanoma invasive to a depth of
.74  mm.  The surrounding surface shows areas of residual radial growth phase/in
itu  melanoma.
ifferences in the possible diagnoses, as well as examination of tis-
ue morphology. Additionally, we strongly encourage obtaining a
econd opinion of another histopathologist, preferably at a high
olume center.
. Case presentation
.1. Case 1
A 68-year-old male with a lesion on the posterior left forearm that
presented one year ago and was initially treated with cryother-
apy. Eight weeks prior, the patient noticed the lesion enlarging.
Patient has a past medical history of atrial ﬁbrillation treated with
anticoagulant therapy as well as squamous cell carcinoma of the
skin. Patient has a past surgical history of pacemaker placement,
heart valve replacement, splenectomy, and nasal septal devia-
tion repair. He has family history of a cardiac disorder and colon
cancer. Patient denies smoking.
A shave biopsy of 2 cm × 2 cm on the left forearm identiﬁed super-
ﬁcial spreading melanoma of 2.1 mm thickness, high mitotic
index, and ulceration with positive margins that was staged as
T3a. A wide local excision with 2 cm margins and sentinel lymph
node biopsy due to positive margins & intermediate thickness
was performed. The tumor size was 1.21 cm with a maximum
thickness at 2.3 mm and staged at pT3aN0M0. Pathology of the
re-excisional biopsy showed focal residual malignant melanoma
invasive to 0.74 mm with atypia and overlying epidermis with
residual in situ melanoma (Fig. 1). Peripheral and deep margins
were uninvolved. No lymphovascular invasion or microsatelli-
tosis was identiﬁed. 2 non-sentinel lymph nodes were examined
and showed no regional lymph node metastasis. 1 sentinel lymph
node showed 0.4 mm focus within nodal capsule with positive
S100 and MART-1 staining that was suspicious for capsular nevus
vs. less likely metastases due to lack of cellular atypia and other
morphological signs. These slides were sent to an outside institu-
tion for second opinion. The reports identiﬁed, ﬁrst, the primaryon  H & E stained section levels but appear to have small round nuclei.
tumor to be a residual melanoma invasive to 0.74 mm,  classi-
ﬁed as lentigo maligna melanoma. Morphological observations
of sentinel lymph nodes were consistent with capsular nevus
(Fig. 2). Sentinel lymph node was  positive for Melan-A, S100
(Fig. 3), and MART-1 (Fig. 4). However, it was  negative for HMB-
45, which helped conﬁrm a benign diagnosis. The second opinion
agreed that the sentinel node was  more consistent with capsular
nevus rather than malignant melanoma.
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Fig. 5. Case 2: H & E of sentinel lymph node shows bland melanocytes within the
capsule with uncertain signiﬁcance.ig. 4. Case 1: MART-1 immunostain shows 0.4 mm focus of small bland appearing
ells within the capsule that are not discretely identiﬁable on H & E stained section
evels but appear to have small round nuclei.
.2. Case 2
A 57-year-old male with a gradually enlarging lesion on the right
ﬂank. Patient denied any pain or associated symptoms with the
lesion. Patient has a past medical history of hypertension, past
surgical history of knee surgery, and family history of cardiac dis-
orders. Patient denies smoking, alcohol, or illicit drug use. There
were no palpable cervical, supraclavicular or axillary nodes on
physical exam.
A shave biopsy of 2 cm × 1.5 cm identiﬁed superﬁcial spreading
melanoma of 1.01 mm thickness with <1 mm2 mitotic index, and
non-ulcerated. Deep and lateral margins were positive and the
tumor was clinically staged at T2a. A wide local excision with
2 cm margins and sentinel lymph node biopsy was performed
due to intermediate thickness melanoma. The wide local excision
pathologically demonstrated no residual malignant melanoma,
no lymphovascular invasion, or microsatellosis. The peripheral
and deep margins were uninvolved. Four non-sentinel lymph
nodes all showed no metastatic melanoma; three were S-100
negative, and all four were SOX10 and MART-1 negative. One sen-
tinel node demonstrated bland melanocytes within the capsule
of uncertain signiﬁcance and could represent benign nevus cells
but identiﬁcation was not certain (Fig. 5). A consultative review
was sent to an outside institution. These reports stated that the
excisional biopsy demonstrated no residual melanoma and the
sentinel node showed aggregates of melanocytic cells present
within the capsule. These aggregates were of a lesser degree of
atypia compared to primary tumor but were S100 (Fig. 6) and
MART-1 (Fig. 7) positive. They concluded that the cells were more
likely capsular nevus vs. metastatic melanoma.
. Discussion
Benign nevus cell aggregates within lymph nodes is a well-
escribed ﬁnding; however, there are no standardized ways to
istinguish them from metastatic melanocytes and thus pose a
iagnostic pitfall to pathologists. While there are many morpho-
ogic guidelines to recognize nodal nevus cells, there are someFig. 6. Case 2: S100 immunostain of sentinel lymph node capsule showed to be
positive.
cases where the diagnosis may  not be as straightforward and the
prediction of behavior of certain cells may  not be accurate solely
based on histopathological ﬁndings [9]. Current data trends have
deﬁnitively indicated that patients with benign nevus aggregates
in the sentinel nodes do not require additional lymphadenectomies
and pharmacologic therapies as their prognosis is similar to that
of patients with negative sentinel lymph nodes [8]. Assigning a
diagnosis of malignancy might seem like the safer approach, but
it can result in excessive treatment, which leads to the possibility
of surgical complications, anxiety, discomfort, and ﬁnancial insta-
bility for the patient. Thus, a careful diagnostic approach should be
taken in patients with questionable sentinel lymph nodes to con-
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Fig. 7. Case 2: MART-1 immunostain for sentinel lymph node shown to be positive.
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[8] T.L. Bowles, Y. Xing, C.-Y. Hu, et al., Conditional survival estimates improve
over 5 years for melanoma survivors with node-positive disease, Ann. Surg.
Oncol. 17 (8) (2010) 2015–2023.
[9] R.A. Scolyer, R. Murali, S.W. McCarthy, J.F. Thompson, Histologically
ambiguous (borderline) primary cutaneous melanocytic tumors: approachesrm any metastatic disease before starting aggressive therapy to
reat metastatic melanoma. Current methods of distinguishing the
wo based solely on histology may  be insufﬁcient due to the similar
athologic patterns between melanoma and capsular nevi cells.
The exact mechanism by which nevus cells arrive to the lymph
odes has not been established, but the mechanical transport the-
ry has been the most favored amongst most studies [3,4,7,9]. This
heory proposes that a neoplastic melanocyte displaces the adja-
ent nevus cells, which are then transported into the lymphatics.
t is then assumed that the benign nevi hone to the ﬁbrous tissue
f the capsule, trabeculae, or even sometimes node parenchyma,
hich may  explain the high prevalence in regional sentinel lymph
odes [5]. Nevus cells have a particular morphology and lack the
dentifying characteristics associated with melanoma, including
arge cells, numerous mitotic ﬁgures, large nuclear to cytoplasm
atio, and pleomorphism [12].
Immunohistochemistry studies can play a helpful role, but are
ot deﬁnitive in distinguishing nodal nevus from melanoma. Nodal
evi have shown to be positive for S-100 and MART-1 stains, which
re both thought to be highly sensitive markers for metastatic
elanocytes. Thus, these are inconclusive markers for correctly
istinguishing benign from malignant cells [5,6]. Additional studies
ave shown that nevus cells are often absent or only focally positive
or HMB-45 (gp-100) while most metastatic melanoma often stain
trongly for HMB-45. However, not all metastatic melanomas are
ositive for HMB-45, thus an absence does not rule out the diagno-
is of melanoma [5,13]. Studies have also demonstrated that Ki-67
mmunohistochemical (IHC) markers are positive in less than 1%
f benign nevus cells and the lack of Ki-67 may  further conﬁrm
he presence of benign nevus aggregates [5,6]. Furthermore, the
resence of SOX10 protein, as well as MART-1, is strong predictor
f malignant melanoma [14,15]. Many recent studies advocate the
se of these IHC markers to help conﬁrm suspicious lymph node
iopsies. However, no one marker has shown to be diagnostic at
his time and no one study has identiﬁed which ones should be
tandard markers in ambiguous biopsy ﬁndings.PEN  ACCESS
gery Case Reports 29 (2016) 20–24 23
4. Conclusion
These two cases presented a diagnostic dilemma and allow for
discussion regarding the best approach in similar patients where
an absolute diagnosis is difﬁcult. IHC staining should be employed
carefully in making a distinction between benign and metastatic
cells due to some overlap in commonly used markers. The best way
to assign the most accurate diagnosis to the sentinel lymph node
biopsy is to compare both the morphology and staining characteris-
tics between the primary melanoma lesion and the lymph node, as
well as using as many different staining methods as possible. Addi-
tionally, in order to avoid misdiagnosing a patient and performing
unnecessary further therapy, it would be beneﬁcial to get a second
opinion by another histopathologist at a high volume center.
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